Recent health news highlights include a UK hospital-related death due to a cyberattack, Walgreens beating profit estimates ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with ...

Health news includes a cyberattack affecting patient care in London, Walgreens' financial success amid strategic changes, ...

Preventive treatment with Pfizer's Hympavzi can reduce bleeding rates in hemophilia A or B patients with inhibitors, new ...

Pfizer’s Hympavzi, given as a once-weekly subcutaneous injection using a pre-filled pen, works by reducing the amount of TFPI, a naturally occurring protein that prevents blood from clotting too much.

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Pfizer Inc. (NYSE: PFE)today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for ...

Pfizer announces positive results from phase 3 BASIS study of Hympavzi in haemophilia A or B with inhibitors: New York Friday, June 27, 2025, 10:00 Hrs [IST] Pfizer Inc. announced ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with hemophilia A or B with inhibitors.